China NMPA Drug Inspection - Henan Shengwang Pharmaceutical Co., Ltd. - Qingkailing Injection

On November 28, 2017, the Henan Provincial Food and Drug Administration announced findings regarding four batches of substandard drugs from four different companies following quality testing by its provincial inspection agency. Yuzhou Baicaohui Pharmaceutical Co., Ltd. was cited for substandard Agarwood (batch 160522). Yuzhou Jindi Traditional Chinese Medicine Pieces Co., Ltd. produced substandard Mulberry mistletoe (batch 151101) due to appearance issues. Luoyang Kangxin Traditional Chinese Medicine Pieces Co., Ltd.'s Safflower (batch 170101) failed quality tests for excessive acid-insoluble ash content. Finally, Henan Shennong Pharmaceutical Co., Ltd. had substandard Qingkailing Injection (batch 16100201) containing visible foreign matter. As a result, the Henan Provincial Food and Drug Administration directed relevant regulatory bodies to implement immediate risk control measures. These actions included sealing, seizing, and suspending the sale of the identified substandard products. Additionally, the regulatory departments were mandated to investigate and penalize the entities responsible for distributing these samples, ensuring compliance with legal standards. This enforcement highlights the ongoing commitment of the National Medical Products Administration's provincial branch to public health and drug quality in China.